Detail akcie Jazz Pharma online

Business Summary: Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Jazz Pharmaceuticals PLC revenues increased 1% to $1.94B. Net loss totaled $811M vs. income of $154M. Revenues reflect Xywav segment increase from $368.5M to $760.1M, Epidiolex/epidyolex segment increase of 90% to $469.5M, Europe segment increase of 8% to $166.4M, All Others segment increase of 9% to $43M.